Early identification of suboptimal responders to multiple sclerosis (MS) treatment is critical for optimizing therapeutic decisions. The Rio score (RS) and modified Rio score (MRS) were developed to discriminate the responses to interferon-beta (IFNB) treatment in MS patients. This study was performed to evaluate the utility of RS and MRS in daily clinical practice in Korea.
This was a real-world setting, multicenter, retrospective study of MS patients treated with IFNB from 10 hospitals in Korea. We investigated whether the RS and MRS at the early stage of IFNB therapy could predict treatment responses over 3 years. Suboptimal treatment responses at 3 years were defined as the presence of clinical relapse and/or EDSS progression and/or patients who had been treated with INFB for at least for 1 year and therapy was switched due to perceived treatment failure during the 2 years of follow-up.
Seventy patients (50 females and 20 males) were enrolled; 92% (12/13) of patients with high RS and 86% (12/14) of patients with high MRS (score 2 or 3) were suboptimal responders, whereas 93% (53/57) of patients with low RS and 93% (52/56) patients with low MRS (score 0 or 1) showed optimal responses. New active lesions on MRI with clinical relapse in high RS and MRS were the most common combination in suboptimal responders.
Citation: Hyun J-W, Kim S-H, Jeong IH, Ahn S-W, Huh S-Y, Park MS, et al. (2015) Utility of the Rio Score and Modified Rio Score in Korean Patients with Multiple Sclerosis. PLoS ONE 10(5): e0129243. https://doi.org/10.1371/journal.pone.0129243
Academic Editor: Orhan Aktas, University of Düsseldorf, GERMANY
Received: January 29, 2015; Accepted: May 6, 2015; Published: May 26, 2015
Copyright: © 2015 Hyun et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Data Availability: All relevant data are within the paper and its Supporting Information files.
Funding: No current funding sources for this study.
Competing interests: Dr. HJ Kim has received honoraria for speaking or consulting from Bayer Schering Pharma, Biogen Idec, Genzyme, Merck Serono, Novartis, MedImmune, and Teva-Handok and has received research grants from Genzyme, Merck Serono, and Kael-GemVax. He serves on a steering committee for MedImmune and serves as an editorial board member of Multiple Sclerosis Journal—Experimental, Translational and Clinical. Dr. NH Kim has received honoraria for speaking or consulting from Bayer Schering Pharma, UCB, Merck Serono, and Novartis. Dr. J Oh has received honoraria for speaking or consulting from Genzyme. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.
Interferon-beta (IFNB) is the established first-line therapy for relapsing-remitting multiple sclerosis (MS) . However, the individual response to interferon-beta is heterogeneous . There is now a broad range of treatment options available for MS , and it becomes imperative to identify suboptimal responders to first-line therapy early during the course of treatment to optimize therapeutic decisions [4,5]. Clinical and MRI measures have proven helpful in detecting poor-responders among MS patients during early in the course of treatment with IFNB .
The Rio score (RS) is a recently developed scoring system that consists of a combination of clinical and MRI parameters to predict suboptimal responders . The Modified Rio score (MRS) is a simplified version of RS, which excludes expanded disability status scale (EDSS) progression and modified items of relapses and MRI lesions . These scores were estimated after 1 year of IFNB therapy with the aim of identifying patients that will have ongoing disease activity and become suboptimal responders in the ensuing 2 years.
Previous studies in Asia demonstrated that, after careful exclusion of neuromyelitis optica spectrum disorder (NMOSD), the therapeutic response to IFNB does not differ fundamentally between Asian and Caucasian populations with MS [9–11]. Furthermore, we showed recently that the McDonald criteria for diagnosis of MS [12,13] were also suitable for evaluation of Korean MS patients [9,14]. Therefore, therapeutic monitoring of IFNB in MS patients using RS and MRS would be also helpful to evaluate Asian MS populations, but the previous validation of RS and MRS was performed only in Western MS patients based mainly on a prospective research cohort [7,8]. The present study was performed to evaluate the utility of RS and MRS in daily clinical practice in a Korean multicenter cohort.
The Institutional Review Board of National Cancer Center approved the study protocol (NCC2014-0046) and waived the requirement for informed consent due to the use of de-identified data.
Study design and patients
This was a real-world setting, multicenter, retrospective study of MS patients treated with IFNB. Patients were recruited from 10 referral hospitals in Korea. Patients with relapsing MS treated with IFNB over 1 year with a follow-up duration of least 3 years with adequate medical records and MRI scans were enrolled in this study [12,13]. Due to the retrospective nature of this study, patients who had a baseline and follow-up brain MRI after 6–15 months of IFNB (not confined to the patients who had a follow-up MRI after 12 months) were included in the cohort. Patients who had received other disease modifying treatments for MS before IFNB were excluded.
Defining scoring systems and risk groups
RS and MRS were defined as described previously (Table 1) [7,8]. RS and MRS were not confined after 12 months but after 6–15 months of IFNB therapy according to the follow-up duration of MRI. According to the scores, patients were divided into a low-risk group (score 0 or 1), or high-risk group (score 2 or 3) for a suboptimal response to treatment after 6–15 months of INFB. To decrease the inter-observer variability, a web-based central database for MRI was established and MRI scans were independently analyzed by two neurologists.
Suboptimal responses at 3 years were defined as the presence of clinical relapse (accompanied by an appropriate new neurological abnormality; lasting at least 24 hours in the absence of fever; and preceded by stability or improvement for at least 30 days) and/or 6 months confirmed EDSS progression (1 point for patients with 1-year EDSS < 6, 0.5 points for EDSS ≥ 6) during the ensuing 2 years of IFNB therapy [1,7,8]. Due to the retrospective nature of this study, if we had used the previous definition of suboptimal responders, the sensitivities of RS and MRS would have been too narrow to evaluate suboptimal responders in daily practice. Therefore, we also included nine patients who had been treated with INFB for at least for 1 year and therapy was switched due to perceived treatment failure (clinical relapses) during the 2 years of follow-up, as suboptimal responders to IFNB. In addition, we examined whether the high-risk groups of RS and MRS became suboptimal responders and RS and MRS were well matched.
A total of 70 MS patients treated with IFNB from 10 centers was enrolled in this study. Among the 70 patients, 50 were women and 20 were men. The mean age of onset was 29.5 ± 9.6 years and mean follow-up duration was 6.5 ± 2.8 years. The median baseline EDSS score at commencement of IFNB treatment was 2 (range 0–5) and the median interval from onset to IFNB therapy was 9 (range 1–92) months. (Table 2)
First, sixteen (23%) of the seventy patients were classified as suboptimal responders after 3 years of IFNB therapy and high-risk groups of RS and MRS predicted suboptimal treatment response well. The high-risk group of RS consisted of 13 (19%) patients and the low-risk group consisted of 57 (81%). Similarly, 14 of 70 (20%) patients were included in the high-risk group of MRS and the low-risk group of MRS consisted of 56 (80%) patients. Twelve of thirteen (92%) patients in the high-risk group of RS and 12 of 14 (86%) patients in the high-risk group of MRS showed suboptimal responses. In contrast, 53 of 57 (93%) patients in the low-risk group of RS and 52 of 56 (93%) patients in the low-risk group of MRS were optimal responders. There was a significant difference between the high and low score groups in terms of predicting suboptimal responses (p < 0.001)(Table 3). In addition, the high-risk groups of RS and MRS showed high sensitivity (both 75%) and specificity (98%, 96%, respectively) in terms of predicting suboptimal responders (Table 4). The combination of new active lesions on follow-up MRI and relapses in RS as well as MRS were the most common combinations of suboptimal responders (Table 5).
Second, RS and MRS were well matched in high- or low-risk groups, respectively (Fig 1). Sixty-one of the seventy (87%) patients had the same scores on RS and MRS. RS and MRS differed in nine patients, but there was no overlap between the low- and high-risk groups of RS and MRS except one case (1%) with a mixed low-risk group of RS and high-risk group of MRS. The patient who had different RS and MRS experienced two clinical relapses during 1 year of IFNB with two new active lesions on follow-up MRI scan, and therefore RS was 1 but MRS was estimated as 2; the patient finally became an optimal responder.
We demonstrated that RS and MRS measured at 6–15 months of IFNB therapy were good predictors of treatment response in the ensuing 2 years in Korean MS patients. Despite IFNB therapy, patients with ongoing disease activity which included new active lesions on MRI, relapse, or EDSS progression at the early stage, appeared to significantly increase the chance of suboptimal response at 3 years. The results of the present study suggest that both RS and MRS are useful for estimating the ensuing response to INFB in daily clinical practice in Korean MS patients, similar to those from Western countries [7,8].
While there was a considerable degree of heterogeneity within the definitions used, 16%- 29% of Western patients receiving IFNB showed ongoing disease activity in the first 2 years [15–17]. In the present study, 23% of patients were estimated as a high-risk group for suboptimal response using RS or MRS during early treatment with IFNB. This proportion of potential suboptimal responders at the early stage of treatment was consistent with previous Western studies, and the majority of these patients (86–92%) were found to show suboptimal responses over 3 years of IFNB therapy.
The sensitivity (75%) and specificity (> 96%) of RS and MRS confirmed their potential to predict suboptimal response to IFNB therapy. A previous study in patients with 4 years of follow-up from the initiation of treatment revealed low sensitivity (24%) but high specificity (97%) in MRS . The higher sensitivity of RS and MRS in the current study may have been associated with the different definition of suboptimal response and timing of MRI monitoring compared to the previous study . Previous studies with RS or MRS based on prospective research cohorts unified the follow-up duration of MRI scans as 6 or 12 months [7,8]. However, in this real-world setting, unified follow-up of MRI was difficult in individual patients, and serial MRI may often be compared using different protocols. Despite this limitation, the present study indicated that both scales were useful for predicting individuals at high-risk of a suboptimal response to IFNB in daily clinical practice.
On the other hand, 4 (7%) out of 56 patients who were considered at low-risk (score 0 or 1) by RS and MRS during early treatment ultimately had disease activity over 3 years of follow-up. To resolve this issue, Sormani and colleagues recently suggested that refining the scores may allow better prediction of treatment response . Patients with a score of 1 estimated by MRS who were classified as being at intermediate risk, may require additional evaluation after 6 months; if the patient has then experienced ≥1 relapse in the additional 6 months or ≥2 new T2 lesions have appeared at the 6 month MRI scan, then patient can be associated with the high-risk group .
The major difference between RS and MRS is involvement of EDSS progression . Some patients may show EDSS progression during early IFNB therapy in the absence of new active lesions on follow-up MRI scans and clinical relapse. Moreover, score 0 on RS is in line with the “no evidence of disease activity” or “freedom from disease activity” which has been recently considered as a potential ideal measure of the therapeutic responses . In this study, the odds ratio for optimal responders who had RS of 0 was 9.4 (95% CI 2.4–37.5, p = 0.001). However, estimation of EDSS may not always be available in daily clinical practice and involve high inter-rater variability . For these reasons, MRS was developed based on the recent observation that a combination of new active MRI lesions and relapses seem to be a surrogate for disability progression [8,16]. In the present study, RS and MRS independently predicted suboptimal responders and their scores were well matched. Thus, complementary use of these scores would facilitate detection of future suboptimal responders in daily practice.
This study had some methodological shortcomings due to its retrospective nature. Follow-up MRI scans of MS patients in early treatment with IFNB were not always performed in daily clinical practice; therefore, the number of the patients enrolled in this study was small. Therefore, ordinal logistic regression to analyze the odds of the various scores in predicting suboptimal response and also analyzing differences by baseline variables was not available. However, considering the 20–30 times lower prevalence of MS in Korea than those in Western countries, 70 cases could be comparable to a few hundreds cases in countries with higher MS prevalence [21,22].
In conclusion, evaluation of RS and/or MRS in daily clinical practice is useful to predict the response to INFB therapy and therefore would be helpful to optimize MS therapy.
Financial Disclosure: Drs. Hyun, SH Kim, Jeong, Ahn, Huh, MS Park, Eom, Joo, JY Cho, EB Cho, Min, BJ Kim, KD Park report no disclosures. Dr. HJ Kim has received honoraria for speaking or consulting from Bayer Schering Pharma, Biogen Idec, Genzyme, Merck Serono, Novartis, MedImmune, and Teva-Handok and has received research grants from Genzyme, Merck Serono, and Kael-GemVax. He serves on a steering committee for MedImmune and serves as an editorial board member of Multiple Sclerosis Journal—Experimental, Translational and Clinical. Dr. NH Kim has received honoraria for speaking or consulting from Bayer Schering Pharma, UCB, Merck Serono, and Novartis. Dr. J Oh has received honoraria for speaking or consulting from Genzyme. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Conceived and designed the experiments: JWH HJK SHK. Performed the experiments: JWH HJK SHK IHJ SWA SYH MSP YIE ISJ JYC EBC JHM BJK NHK JO KDP. Analyzed the data: JWH HJK SHK IHJ SWA SYH MSP YIE ISJ JYC EBC JHM BJK NHK JO KDP. Contributed reagents/materials/analysis tools: JWH HJK SHK. Wrote the paper: JWH HJK SHK IHJ SWA SYH MSP YIE ISJ JYC EBC JHM BJK NHK JO KDP.
- 1. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 1993; 43: 655–661. pmid:8469318
- 2. Sormani MP, Bruzzi P, Beckmann K, Kappos L, Miller DH, Polman C, et al. The distribution of magnetic resonance imaging response to interferonbeta-1b in multiple sclerosis. J Neurol 2005; 252: 1455–1458. pmid:16021360
- 3. Wingerchuk DM, Carter JL. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Mayo Clin Proc 2014; 89: 225–240. pmid:24485135
- 4. Rio J, Comabella M, Montalban X. Predicting responders to therapies for multiple sclerosis. Nat Rev Neurol 2009; 5: 553–560. pmid:19794514
- 5. Rudick RA, Polman CH. Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis. Lancet Neurol 2009; 8: 545–559. pmid:19446274
- 6. Rio J, Nos C, Tintore M, Tellez N, Galan I, Pelayo R, et al. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann Neurol 2006; 59: 344–352. pmid:16437558
- 7. Rio J, Castillo J, Rovira A, Tintore M, Sastre-Garriga J, Horga A, et al. Measures in the first year of therapy predict the response to interferon beta in MS. Mult Scler 2009; 15: 848–853. pmid:19542263
- 8. Sormani MP, Rio J, Tintore M, Signori A, Li D, Cornelisse P, et al. Scoring treatment response in patients with relapsing multiple sclerosis. Mult Scler 2013; 19: 605–612. pmid:23012253
- 9. Kim SH, Huh SY, Kim W, Park MS, Ahn SW, Cho JY, et al. Clinical characteristics and outcome of multiple sclerosis in Korea: does multiple sclerosis in Korea really differ from that in the Caucasian populations? Mult Scler 2013; 19: 1493–1498. pmid:23407702
- 10. Saida T, Itoyama Y, Tashiro K, Kira J, Hao Q; Interferon Beta-1a Multiple sclerosis study group of Japan, et al. Intramuscular interferon beta-1a is effective in Japanese patients with relapsing-remitting multiple sclerosis: a pre-treatment versus treatment comparison study of gadolinium-enhanced MRI brain lesions. Mult Scler 2012; 18: 1782–1790. pmid:22492130
- 11. Jarernsook B, Siritho S, Prayoonwiwat N. Efficacy and safety of beta-interferon in Thai patients with demyelinating diseases. Mult Scler 2013; 19: 585–592. pmid:22968544
- 12. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005; 58: 840–846. pmid:16283615
- 13. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292–302. pmid:21387374
- 14. Huh SY, Kim SH, Kim WJ, Lee SH, Park MS, Ahn SW, et al. Evaluation of McDonald MRI criteria for dissemination in space in Korean patients with clinically isolated syndromes. Mult Scler 2014; 20: 492–495. pmid:23886829
- 15. Rudick RA, Lee JC, Simon J, Ransohoff RM, Fisher E. Defining interferon beta response status in multiple sclerosis patients. Ann Neurol 2004; 56: 548–555. pmid:15389896
- 16. Sormani MP, Li DK, Bruzzi P, Stubinski B, Cornelisse P, Rocak S, et al. Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis. Neurology 2011; 77: 1684–1690. pmid:21975200
- 17. Rio J, Rovira A, Tintore M, Huerga E, Nos C, Tellez N, et al. Relationship between MRI lesion activity and response to IFN-beta in relapsingremitting multiple sclerosis patients. Mult Scler 2008; 14: 479–484. pmid:18562504
- 18. Sormani MP, Signori A, Stromillo ML, Stefano ND. Refining response to treatment as defined by the Modified Rio Score. Mult Scler 2014; 19: 1246–1247.
- 19. Havrdova E, Galetta S, Stefoski D, Comi G. Freedom from disease activity in multiple sclerosis. Neurology 2010; 74: S3–S7. pmid:20421571
- 20. Noseworthy JH, Vandervoort MK, Wong CJ, Ebers GC. Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group. Neurology 1990; 40: 971–975. pmid:2189084
- 21. Kim NH, Kim HJ, Cheong HK. Prevalence of multiple sclerosis in Korea. Neurology. 2010; 75: 1432–8. pmid:20956788
- 22. Pugliattia M, Rosatia G, Carton H, Riise T, Drulovic J, Vecsei L, et al. The epidemiology of multiple sclerosis in Europe. Eur J Neurol 2006, 13: 700–722. pmid:16834700